Details of Disease

General Information of Disease (ID: DISLL965)

Disease Name Hypertension
Disease Class BA00-BA04: Hypertension
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISLL965: Hypertension
ICD Code
ICD-11
ICD-11: BA00-BA04
ICD-9
ICD-9: 401
Expand ICD-9
401
Disease Identifiers
MONDO ID
MONDO_0012109
UMLS CUI
C1837479
OMIM ID
608742
MedGen ID
325180

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 99 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Acebutolol DM0TI4U Approved Small molecular drug [1]
Aldosterone DM9S2JW Approved Small molecular drug [2]
Aliskiren DM1BV7W Approved Small molecular drug [3]
Alseroxylon DMB47TQ Approved NA [4]
Amlodipine DMBDAZV Approved Small molecular drug [5]
Amosulalol DML8QSZ Approved Small molecular drug [6]
Atenolol DMNKG1Z Approved Small molecular drug [7]
Azilsartan DMOIX5S Approved Small molecular drug [8]
Benazepril DMH1M9B Approved Small molecular drug [9]
Betaxolol DM6EUL5 Approved Small molecular drug [10]
Bevantolol DMZFICR Approved Small molecular drug [11]
Bisoprolol DM3UZ95 Approved Small molecular drug [12]
Bopindolol DMIFYLX Approved Small molecular drug [1]
Cadralazine DM7BJFR Approved Small molecular drug [1]
Candesartan DMRK8OT Approved Small molecular drug [13]
Captopril DM458UM Approved Small molecular drug [14]
Celiprolol hcl DMD5LBX Approved Small molecular drug [1]
Chlorthalidone DM4DMBT Approved Small molecular drug [15]
Clevidipine butyrate DMW4M97 Approved Small molecular drug [16]
Clonidine DM6RZ9Q Approved Small molecular drug [17]
Cryptenamine Acetates DMHCTAL Approved NA [1]
Debrisoquin DMC50ME Approved Small molecular drug [18]
Deserpidine DMRH7CV Approved Small molecular drug [19]
Diazoxide DML1538 Approved Small molecular drug [20]
Dihydralazine DMZIXU9 Approved Small molecular drug [1]
Diltiazem DMAI7ZV Approved Small molecular drug [21]
Dipyridamole DMXY30O Approved Small molecular drug [22]
Docarpamine DMS5IEB Approved Small molecular drug [1]
Doxazosin DM9PLRH Approved Small molecular drug [23]
Enalapril DMNFUZR Approved Small molecular drug [24]
Enalaprilat DMFYAM1 Approved NA [25]
Eprosartan DM07K2I Approved Small molecular drug [26]
Felodipine DMOSW35 Approved Small molecular drug [27]
Fenoldopam DMFAOKP Approved Small molecular drug [28]
Fenquizone DM86G2H Approved Small molecular drug [1]
Forasartan DMRBJNZ Approved Small molecular drug [29]
Fosinopril DM9NJ52 Approved Small molecular drug [30]
Guanadrel Sulfate DM6S157 Approved Small molecular drug [31]
Hydralazine DMU8JGH Approved Small molecular drug [32]
Hydrochlorothiazide DMUSZHD Approved Small molecular drug [33]
Indapamide DMGN1PW Approved Small molecular drug [34]
Irbesartan DMTP1DC Approved Small molecular drug [35]
Isradipine DMA5XGH Approved Small molecular drug [36]
Ketanserin DMVLMW6 Approved Small molecular drug [37]
Labetalol DMK8U72 Approved Small molecular drug [38]
Lercanidipine DMPWSEM Approved Small molecular drug [39]
Lisinopril DMUOK4C Approved Small molecular drug [1]
Losartan DM72JXH Approved Small molecular drug [40]
Methoxamine DMF5XQH Approved Small molecular drug [41]
Methyclothiazide DMN7SDE Approved Small molecular drug [42]
Methyldopa DM5I621 Approved Small molecular drug [43]
Methyldopate Hydrochloride DM8XI09 Approved Small molecular drug [1]
Metolazone DMB39LO Approved Small molecular drug [44]
Metoprolol DMOJ0V6 Approved Small molecular drug [45]
Micardis telmisartan DM3O6CY Approved NA [46]
Minoxidil DMA2Z4F Approved Small molecular drug [47]
Moexipril DM26E4B Approved Small molecular drug [48]
NAFTOPIDIL DMQ8R4E Approved Small molecular drug [1]
Nebivolol DM7F1PA Approved Small molecular drug [49]
Nisoldipine DM7ISKJ Approved Small molecular drug [50]
Nitrendipine DM21C09 Approved Small molecular drug [51]
Nitric Oxide DM1RBYG Approved Small molecular drug [52]
Nitroprusside DMLUA2J Approved NA [53]
Oxprenolol DM51OQW Approved Small molecular drug [54]
Pargyline DMM0HR1 Approved Small molecular drug [1]
Penbutolol DM4ES8F Approved Small molecular drug [55]
Perindopril DMOPZDT Approved Small molecular drug [56]
Pindolol DMD2NV7 Approved Small molecular drug [57]
Polythiazide DMCH80F Approved Small molecular drug [58]
Prazosin DMCD9YG Approved Small molecular drug [1]
Quinapril DMR8H31 Approved Small molecular drug [59]
Quinethazone DMWCOSR Approved Small molecular drug [60]
Remikiren DMNAKLY Approved Small molecular drug [61]
Rescinnamine DMG7SQK Approved Small molecular drug [62]
Reserpine DM6VM38 Approved Small molecular drug [63]
Rilmenidine DM13PQW Approved Small molecular drug [1]
Saprisartan DM4087K Approved Small molecular drug [64]
SARALASIN DMKS1DV Approved Small molecular drug [65]
Saralasin Acetate DMKZROL Approved Small molecular drug [1]
Sodium nitrite DMS9J43 Approved Small molecular drug [66]
Sodium nitroprusside DMGA9X0 Approved Small molecular drug [67]
Sparsentan DMMP51W Approved Small molecular drug [68]
Spirapril DM5XLTY Approved Small molecular drug [69]
Tasosartan DMM13DI Approved Small molecular drug [70]
Telmisartan DMS3GX2 Approved Small molecular drug [71]
Terbutyline DMVPWLZ Approved NA [1]
Terlipressin DMT9FH3 Approved Small molecular drug [72]
TERTATOLOL DM2L3D5 Approved Small molecular drug [73]
Tiamenidine DMBM27N Approved Small molecular drug [1]
Trandolapril DM4L6EU Approved Small molecular drug [74]
Triamterene DM2HU9I Approved Small molecular drug [75]
Trichlormethiazide DMHAQCO Approved Small molecular drug [76]
Urapidil DMD59GI Approved Small molecular drug [1]
Valsartan DMREUQ6 Approved Small molecular drug [77]
Verapamil DMA7PEW Approved Small molecular drug [78]
Xipamide DMFS51Y Approved Small molecular drug [79]
Azelnidipine DMA12HL Phase 4 NA [1]
Celiprolol DMYTGW0 Phase 4 NA [1]
Levamlodipine DM92S6N Phase 4 Small molecular drug [80]
------------------------------------------------------------------------------------
⏷ Show the Full List of 99 Drug(s)
This Disease is Treated as An Indication in 62 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AG-SCT101 DM60SPV Phase 3 NA [81]
Binodenoson DMVHF8G Phase 3 Small molecular drug [82]
BQ788 DM6KRLW Phase 3 Small molecular drug [83]
Candoxatril DMHJCGV Phase 3 Small molecular drug [84]
Human-cl rhFVIII DMA58I8 Phase 3 NA [85]
Pratosartan DMOMDXI Phase 3 Small molecular drug [86]
PRM-125 DMYSW3W Phase 3 NA [87]
TAK-491 DMCF6SX Phase 3 Small molecular drug [88]
BUCINDOLOL DMV52CP Phase 2/3 Small molecular drug [89]
CY-1503 DML906E Phase 2/3 NA [90]
AIR-001 DM5ON6G Phase 2 NA [91]
Angiotensin therapeutic vaccine DMHT978 Phase 2 NA [92]
Aprocitentan DMEJICQ Phase 2 NA [93]
AR9281 DMJHA6Q Phase 2 Small molecular drug [94]
B244 DMGFWVJ Phase 2 NA [93]
Baxdrostat DM7A4QE Phase 2 Small molecule [95]
CELIKALIM DMDB6H0 Phase 2 Small molecular drug [96]
CL-329167 DMSF7WJ Phase 2 Small molecular drug [97]
CP-80794 DMT3ORQ Phase 2 Small molecular drug [98]
CYT-006-AngQb DMIRSWE Phase 2 Vaccine [99]
FK-788 DM5DIR0 Phase 2 Small molecular drug [100]
FR139317 DMEL5SV Phase 2 Small molecular drug [101]
Gallopamil DMXBR27 Phase 2 Small molecular drug [102]
GR-MD-02 DM9QF65 Phase 2 Protein [103]
INT0001/2004 DMVJKTO Phase 2 NA [104]
ION904 DMJUJT2 Phase 2 RNA interference [105]
IONIS-AGT-LRX DMYPCK2 Phase 2 NA [93]
Kybiqo DMRC19N Phase 2 NA [93]
L-NAME DM01SR6 Phase 2 Small molecular drug [106]
LFF-269 DMIZNKM Phase 2 NA [107]
LHW090 DM11LCS Phase 2 NA [93]
MLS-101 DMCP2BJ Phase 2 NA [108]
Nexopamil DML5S71 Phase 2 Small molecular drug [109]
OJP-2028 DMM9I9E Phase 2 NA [110]
PB1046 DM8MJ3F Phase 2 Recombinant protein [111]
PD-145065 DMWVBTQ Phase 2 Small molecular drug [112]
PL-3994 DMHUCQS Phase 2 NA [113]
QGC-001 DMAFUHK Phase 2 NA [114]
Rostafuroxin DMKQXDB Phase 2 Small molecular drug [115]
RP-49356 DM4N6PF Phase 2 Small molecular drug [116]
SPP-600 DMOVQP8 Phase 2 NA [117]
XXB750 DMA3W2D Phase 2 NA [118]
YM-358 DMS7609 Phase 2 Small molecular drug [119]
YM-430 DMKJF6H Phase 2 NA [120]
YT-146 DM3YVKQ Phase 2 Small molecular drug [121]
Zilebesiran DMS2QRT Phase 2 RNA interference [122]
2-hydroxyoleic acid DMCLKA4 Phase 1/2 Small molecular drug [123]
KBP-5074 DMI9FXE Phase 1/2 NA [93]
AF-130 DM8LG2I Phase 1 NA [93]
APN01 DMHPL66 Phase 1 NA [124]
Carmoxirole DMU6ZMX Phase 1 Small molecular drug [125]
CLP-1004 DM2QBMI Phase 1 NA [126]
DA-727 DM9KS1A Phase 1 NA [127]
DL-017 DMM8GZT Phase 1 NA [128]
Iptakalim DMHW1LI Phase 1 Small molecular drug [129]
MK-3614 DMF1N8J Phase 1 NA [130]
MK-5478 DM4KEJS Phase 1 NA [131]
MK-7145 DMGP42V Phase 1 Small molecular drug [132]
MK-8150 DMDEAMV Phase 1 NA [133]
MP-157 DM5VXWO Phase 1 NA [134]
VTP-27999 DMQEOD6 Phase 1 Small molecular drug [135]
YM-16151-4 DMNLY9R Phase 1 Small molecular drug [136]
------------------------------------------------------------------------------------
⏷ Show the Full List of 62 Drug(s)
This Disease is Treated as An Indication in 124 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alprenolol DMYJ8Z3 Withdrawn from market Small molecular drug [137]
INDORAMIN DMNSJFD Withdrawn from market Small molecular drug [138]
AE-0047 DMTF9YV Discontinued in Preregistration Small molecular drug [139]
Palonidipine hydrochloride DMUH0KO Discontinued in Preregistration Small molecular drug [140]
Semotiadil DMYBPJ1 Discontinued in Preregistration Small molecular drug [141]
Anipamil DMNEM2C Discontinued in Phase 3 Small molecular drug [142]
S-12968 DMPUED3 Discontinued in Phase 3 Small molecular drug [143]
Ilepatril DMTR50E Discontinued in Phase 2/3 NA [144]
BIBR-363 DMGWFZJ Discontinued in Phase 2 NA [145]
CD-349 DM9P7Z2 Discontinued in Phase 2 Small molecular drug [146]
CGS-25462 DM2OWCV Discontinued in Phase 2 Small molecular drug [147]
E-4177 DM2G7IP Discontinued in Phase 2 Small molecular drug [148]
Elisartan potassium DM0XF8J Discontinued in Phase 2 Small molecular drug [149]
FCE-22716 DMT2Z1L Discontinued in Phase 2 Small molecular drug [150]
FK-352 DMHIUGT Discontinued in Phase 2 Small molecular drug [151]
FK-739 DM7TLF6 Discontinued in Phase 2 Small molecular drug [152]
FK-838 DMS87T9 Discontinued in Phase 2 Small molecular drug [153]
FK-906 DMTEW80 Discontinued in Phase 2 Small molecular drug [154]
Fonsartan DM15LAP Discontinued in Phase 2 NA [155]
FOSOPAMINE DMTYHK4 Discontinued in Phase 2 Small molecular drug [156]
ICI-D-8731 DM3R8TX Discontinued in Phase 2 NA [157]
Idrapril DM7O0UR Discontinued in Phase 2 Small molecular drug [158]
KRH-594 DMIJ6FX Discontinued in Phase 2 Small molecular drug [159]
MC-4232 DMN470R Discontinued in Phase 2 NA [160]
MILFASARTAN DMTX97J Discontinued in Phase 2 Small molecular drug [161]
OBERADILOL MONOETHYL MALEATE DMO8PN9 Discontinued in Phase 2 Small molecular drug [162]
OP-2507 DMQM4OV Discontinued in Phase 2 Small molecular drug [163]
P-1075 DM02ANM Discontinued in Phase 2 Small molecular drug [164]
RIPISARTAN DME5MGP Discontinued in Phase 2 Small molecular drug [165]
Sch-34826 DMZR6GI Discontinued in Phase 2 Small molecular drug [166]
SLX-2101 DM1J0YB Discontinued in Phase 2 NA [167]
Tienoxolol DMLWBYO Discontinued in Phase 2 Small molecular drug [168]
UTIBAPRIL DMOB2K5 Discontinued in Phase 2 Small molecular drug [169]
Zabiciprilat DMBSHJ6 Discontinued in Phase 2 Small molecular drug [170]
ZANKIREN DM9F650 Discontinued in Phase 2 Small molecular drug [171]
ZELANDOPAM HYDROCHLORIDE DM1QXPE Discontinued in Phase 2 Small molecular drug [172]
AC-253 DM704HO Discontinued in Phase 1 NA [173]
AC-625 DMIJB68 Discontinued in Phase 1 NA [174]
AZD1175 DM65MUI Discontinued in Phase 1 NA [175]
CGP-48369 DMY8KO4 Discontinued in Phase 1 Small molecular drug [176]
DuP-532 DM59WQ7 Discontinued in Phase 1 Small molecular drug [177]
GYKI-12743 DMQNX02 Discontinued in Phase 1 Small molecular drug [178]
ICI-D-6888 DMZYA9E Discontinued in Phase 1 NA [179]
KR-30450 DMMD6LR Discontinued in Phase 1 NA [180]
NP-252 DMT8IGE Discontinued in Phase 1 Small molecular drug [181]
PAFENOLOL DM6LQGO Discontinued in Phase 1 Small molecular drug [182]
PF-3392455 DMF92BH Discontinued in Phase 1 NA [183]
RIG-200 DMLQD6F Discontinued in Phase 1 Small molecular drug [184]
Ro-31-6930 DMAJDPN Discontinued in Phase 1 Small molecular drug [185]
RS-8891 DM4P5WO Discontinued in Phase 1 NA [186]
SDZ-WAG-994 DMFLOT4 Discontinued in Phase 1 Small molecular drug [187]
SM-6586 DM6CLX9 Discontinued in Phase 1 Small molecular drug [188]
SPP-1148 DMWQKEN Discontinued in Phase 1 NA [189]
SPP-676 DMKEHGT Discontinued in Phase 1 NA [190]
SUN-9221 DM6BO7R Discontinued in Phase 1 NA [191]
Symakalim DMSPBJ9 Discontinued in Phase 1 NA [192]
TAK-591 DM25DB4 Discontinued in Phase 1 NA [193]
UR-7198 DMXN9Z5 Discontinued in Phase 1 NA [194]
50-235 DMM3UK5 Terminated NA [196]
A-68930 DMUJ94B Terminated Small molecular drug [197]
A-74273 DMBEIFL Terminated Small molecular drug [198]
A-74283 DMS3R15 Terminated NA [199]
A-81282 DMH6LCD Terminated Small molecular drug [200]
A-81988 DM1GLIN Terminated Small molecular drug [201]
ADX415 DM61AV4 Terminated NA [202]
AHR-16303B DMJZ48W Terminated Small molecular drug [203]
AHR-16462B DMJ6BEO Terminated NA [204]
BIBP 3226 DMYBR9D Terminated Small molecular drug [205]
BIBS-222 DM5107E Terminated Small molecular drug [206]
BIBS-39 DM098BL Terminated Small molecular drug [207]
BILA-2157BS DMRV4UL Terminated NA [208]
BMS-180560 DMWDRI0 Terminated Small molecular drug [209]
BMS-182874 DM5PG6C Terminated Small molecular drug [210]
BQ-518 DM3O4BG Terminated Small molecular drug [211]
CEDO-8956 DMN03SH Terminated NA [212]
CGS-30440 DM94WIO Terminated NA [213]
CI-992 DMBHYIJ Terminated Small molecular drug [214]
CI-996 DMCJ7N1 Terminated NA [215]
Ciprokiren DM0NJMG Terminated Small molecular drug [216]
CR-2991 DM51XDU Terminated NA [217]
CR-3834 DMTPDX7 Terminated NA [218]
DHP-218 DM5VFR0 Terminated Small molecular drug [219]
DMP-811 DMO26E7 Terminated Small molecular drug [220]
DU-1777 DM87ZWP Terminated Small molecular drug [221]
ES-1005 DMRP7BX Terminated Small molecular drug [222]
EXP-6803 DM9P4ZN Terminated Small molecular drug [223]
FR-149581 DMBOFSQ Terminated NA [224]
FR-183998 DMCQHG4 Terminated Small molecular drug [225]
GW-660511 DMG5A1Z Terminated NA [226]
JTP-2724 DMG7B61 Terminated NA [227]
JTP-4761 DM6TXKR Terminated NA [228]
Ki-1769 DMQXPJB Terminated Small molecular drug [229]
KRI-1314 DM4QHNG Terminated Small molecular drug [230]
KW-3433 DMS2KEG Terminated Small molecular drug [231]
L-158809 DMQ4LDB Terminated Small molecular drug [232]
L-159689 DM9JE7Y Terminated Small molecular drug [233]
L-163017 DMYB5RV Terminated Small molecular drug [234]
M-216765 DMUIGM3 Terminated NA [235]
ME-3221 DMHX6IC Terminated Small molecular drug [236]
NCX-4215 DMHR3ZQ Terminated NA [237]
NS-004 DMCHLJ4 Terminated Small molecular drug [238]
NY-008 DMNHYS8 Terminated Small molecular drug [239]
Omapatrilat DMAGUY0 Terminated Small molecular drug [240]
PD-155080 DMQCNWD Terminated Small molecular drug [241]
POL-443 DMMH5PN Terminated NA [242]
Ro-46-2005 DMRT6FV Terminated Small molecular drug [243]
RS-93522 DMZHS9U Terminated Small molecular drug [244]
RWJ-46458 DMEO7YD Terminated Small molecular drug [245]
SC-51316 DMB26LO Terminated Small molecular drug [246]
SC-56525 DM25MUA Terminated NA [247]
SL-910102 DMNTGXQ Terminated NA [248]
SM-19712 DMNX93E Terminated Small molecular drug [249]
SQ-28603 DM9DJFS Terminated Small molecular drug [250]
SQ-33351 DM083JB Terminated NA [251]
SQ-33800 DMMRWKP Terminated NA [252]
TCV-295 DMCFGS6 Terminated NA [253]
TJN-220 DM4YQDX Terminated Small molecular drug [254]
UP-275-22 DM37DOC Terminated NA [255]
WAY-126227 DMTY7PE Terminated NA [256]
XR-510 DMA13OD Terminated Small molecular drug [257]
YM-099 DMDXLG2 Terminated NA [258]
Z-6568 DMQ6K8J Terminated NA [259]
ZD-7155 DM5KSCI Terminated Small molecular drug [260]
ZM-224832 DM8V0YA Terminated NA [261]
------------------------------------------------------------------------------------
⏷ Show the Full List of 124 Drug(s)
This Disease is Treated as An Indication in 2 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
KIT-302 DM59ENU Application submitted NA [93]
PD-160170 DMB9Z4C Preclinical Small molecular drug [195]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 24 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
A-82186 DMQ5AJW Investigative NA [262]
ADE-HYPT DM6L76D Investigative NA [263]
AG-SFT103 DMVPJML Investigative NA [263]
AmZaar DM0XODW Investigative NA [263]
BD-NP DMT0S7M Investigative NA [264]
CDRI-93/478 DM3XZ1B Investigative NA [263]
CK-2018509 DMAK95A Investigative NA [263]
DKC-215 DMSNITZ Investigative NA [263]
ES-6864 DMSNM5O Investigative Small molecular drug [265]
EXRD-4605 DMY96KO Investigative NA [266]
GKT-03 DMKE8BW Investigative NA [263]
GTP-0125 DMWTQCU Investigative NA [263]
HL-076 DMIVL59 Investigative NA [263]
HL-130 DMJQOGN Investigative NA [263]
JDP-202 DMFLN91 Investigative NA [263]
LASSBio-294 DM3II1V Investigative Small molecular drug [263]
MetPril DMMDEX3 Investigative NA [263]
RB-105 DMRK3HO Investigative Small molecular drug [267]
RJM-0035-K002 DM2P6I8 Investigative NA [268]
SA-ANP DMERJVM Investigative NA [263]
SPP-800 DMP5VN2 Investigative NA [269]
SR-33805A DMPO4WX Investigative Small molecular drug [270]
TELUDIPINE HYDROCHLORIDE DMT4NWX Investigative Small molecular drug [271]
VII-87-B DMGONV3 Investigative NA [263]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2872).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4812).
4 Drug information of Alseroxylon, 2008. eduDrugs.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6981).
6 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 548).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6901).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6374).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 549).
11 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7129).
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 587).
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5158).
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7147).
16 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 516).
18 Drug information of Debrisoquin, 2008. eduDrugs.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7064).
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2409).
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2298).
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4807).
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7170).
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6322).
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6332).
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 588).
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190).
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 985).
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6896).
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6456).
31 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018104.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7326).
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4836).
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7203).
35 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 203534.
36 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488).
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 88).
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7207).
39 Fixed-dose combination lercanidipine/enalapril. Drugs. 2007;67(1):95-106; discussion 107-8.
40 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590).
41 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 483).
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7235).
43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5217).
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4838).
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 553).
46 Clinical pipeline report, company report or official report of Boehringer-Ingelheim Pharmaceuticals.
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4254).
48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6571).
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7246).
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2524).
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2334).
52 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207141.
53 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073465.
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7255).
55 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7263).
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6367).
57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 91).
58 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7274).
59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6350).
60 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7289).
61 Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9.
62 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7098).
63 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4823).
64 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6899).
65 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 598).
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029132)
67 Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
68 ClinicalTrials.gov (NCT00635232) A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension. U.S. National Institutes of Health.
69 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6575).
70 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6898).
71 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 592).
72 Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):207-17.
73 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 64).
74 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6453).
75 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4329).
76 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7314).
77 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3937).
78 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2406).
79 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7900).
80 ClinicalTrials.gov (NCT01131546) Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension. U.S. National Institutes of Health.
81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034819)
82 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5595).
83 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1010).
84 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6492).
85 ClinicalTrials.gov (NCT02256917) Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A. U.S. National Institutes of Health.
86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002623)
87 ClinicalTrials.gov (NCT05195827) Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension. U.S.National Institutes of Health.
88 ClinicalTrials.gov (NCT02480764) TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension.
89 ClinicalTrials.gov (NCT01970501) Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure. U.S. National Institutes of Health.
90 ClinicalTrials.gov (NCT00226369) Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery. U.S. National Institutes of Health.
91 ClinicalTrials.gov (NCT01725269) Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05. U.S. National Institutes of Health.
92 ClinicalTrials.gov (NCT00702221) Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension. U.S. National Institutes of Health.
93 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
94 ClinicalTrials.gov (NCT00847899) Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance. U.S. National Institutes of Health.
95 Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405.
96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006442 )
97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004990)
98 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001570)
99 ClinicalTrials.gov (NCT00710372) Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension. U.S. National Institutes of Health.
100 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5855).
101 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 998).
102 Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406. JPET December 2005 vol. 315 no. 3 1306-1313.
103 ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health.
104 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030546)
105 ClinicalTrials.gov (NCT05314439) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Monthly Subcutaneous Administration of ION904 in Patients With Uncontrolled Hypertension. U.S.National Institutes of Health.
106 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5213).
107 ClinicalTrials.gov (NCT02047656) To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension. U.S. National Institutes of Health.
108 ClinicalTrials.gov (NCT05001945) A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension. U.S.National Institutes of Health.
109 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
110 ClinicalTrials.gov (NCT00553865) Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets. U.S. National Institutes of Health.
111 Clinical pipeline report, company report or official report of PhaseBio.
112 Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
113 ClinicalTrials.gov (NCT00686803) Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension. U.S. National Institutes of Health.
114 ClinicalTrials.gov (NCT02322450) Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension. U.S. National Institutes of Health.
115 ClinicalTrials.gov (NCT01320397) Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations. U.S. National Institutes of Health.
116 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000232)
117 ClinicalTrials.gov (NCT00376636) Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension. U.S. National Institutes of Health.
118 ClinicalTrials.gov (NCT05562934) A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension. U.S.National Institutes of Health.
119 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002583)
120 Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6.
121 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001363)
122 ClinicalTrials.gov (NCT05103332) A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication. U.S.National Institutes of Health.
123 Sustained activation of sphingomyelin synthase by 2-hydroxyoleic acid induces sphingolipidosis in tumor cells. J Lipid Res. 2013 May;54(5):1457-65.
124 ClinicalTrials.gov (NCT00886353) Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2). U.S. National Institutes of Health.
125 Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist. Eur Heart J. 1992 Sep;13 Suppl D:121-8.
126 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)
127 Clinical pipeline report, company report or official report of Daiichi Sankyo.
128 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
129 Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
130 ClinicalTrials.gov (NCT01033643) A Multiple Dose Study of MK3614 (3614-002). U.S. National Institutes of Health.
131 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031415)
132 ClinicalTrials.gov (NCT01370655) A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009 AM1). U.S. National Institutes of Health.
133 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036316)
134 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034178)
135 ClinicalTrials.gov (NCT01217736) Direct Renin Inhibition and the Kidney. U.S. National Institutes of Health.
136 Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
137 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 563).
138 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 501).
139 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001931)
140 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001157)
141 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000198)
142 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000258)
143 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000221)
144 Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
145 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006457)
146 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000220)
147 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002979)
148 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002106)
149 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002994)
150 Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92.
151 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005374)
152 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002869)
153 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005145)
154 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001939)
155 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005209)
156 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002585)
157 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002063)
158 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002045)
159 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007913)
160 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018951)
161 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002993)
162 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002312)
163 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005417)
164 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001364)
165 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004530)
166 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000196)
167 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022583)
168 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000171)
169 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000394)
170 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000139)
171 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002065)
172 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002584)
173 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001605)
174 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002980)
175 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024090)
176 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005020)
177 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001160)
178 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002059)
179 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002319)
180 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005207)
181 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000291)
182 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002399)
183 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026824)
184 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011948)
185 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000054)
186 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000425)
187 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003507)
188 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002576)
189 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025565)
190 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027192)
191 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006767)
192 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003464)
193 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028308)
194 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010597)
195 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
196 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003913)
197 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6077).
198 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001791)
199 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002258)
200 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002508)
201 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002509)
202 Clinical pipeline report, company report or official report of Shionogi (2011).
203 AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
204 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000297)
205 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1485).
206 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003145)
207 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002512)
208 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006753)
209 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002622)
210 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004811)
211 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006825)
212 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001166)
213 Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82.
214 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002298)
215 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003447)
216 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005529)
217 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018844)
218 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022642)
219 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000422)
220 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002624)
221 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002041)
222 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002295)
223 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000418)
224 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007779)
225 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009190)
226 The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80.
227 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010164)
228 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005981)
229 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002625)
230 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002396)
231 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004961)
232 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001562)
233 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003495)
234 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004951)
235 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001629)
236 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002995)
237 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006273)
238 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4271).
239 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004023)
240 Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5.
241 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005553)
242 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003343)
243 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003082)
244 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002793)
245 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002575)
246 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001569)
247 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004067)
248 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003244)
249 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5272).
250 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000347)
251 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
252 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002406)
253 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002578)
254 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002586)
255 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004864)
256 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004966)
257 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004861)
258 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002582)
259 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007046)
260 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8324).
261 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002886)
262 WO patent application no. 2011,0583,31, Pemirolast for the treatment of systemic low grade inflammation.
263 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
264 A Novel Designer Natriuretic and Diuretic Peptide Based Upon an Alternatively Spliced BNP Without Vascular Vasodilatory Actions. Circulation, 2006, 114:II_270.
265 A highly potent and long-acting oral inhibitor of human renin. Hypertension. 1988 Jun;11(6 Pt 2):708-12.
266 Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301.
267 Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55.
268 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1613).
269 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413).
270 Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43.
271 Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33.
272 I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Clin Ther. 2012 Aug;34(8):1705-19.
273 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032180)